Department of Internal Medicine, Wake Forest Baptist Medical Center, Winston-Salem, NC, USA.
Division of Transplant Surgery, Department of Surgery, Methodist University Hospital Transplant Institute, University of Tennessee Health Science Center, Memphis, TN, USA.
Hepatol Int. 2018 Mar;12(2):97-106. doi: 10.1007/s12072-018-9854-1. Epub 2018 Mar 29.
Non-alcoholic fatty liver disease (NAFLD) is currently one of the leading forms of chronic liver disease, and its rising frequency worldwide has reached epidemic proportions. NAFLD, particularly its progressive variant NASH (non-alcoholic steatohepatitis), can lead to advanced fibrosis, cirrhosis, and HCC. The pathophysiologic mechanisms that contribute to the development and progression of NAFLD and NASH are complex, and as such myriad therapies are under investigation targeting different pathophysiological mechanisms. Incretin-based therapies, including GLP-1RAs and DPP-4 inhibitors and the inhibition of ASK1 pathway have provided two such novel mechanisms in the management of this disease, and will remain focus of this review.
非酒精性脂肪性肝病（NAFLD）目前是最主要的慢性肝病形式之一，其在全球的发病率呈流行趋势。NAFLD，特别是其进行性变异型 NASH（非酒精性脂肪性肝炎），可导致晚期纤维化、肝硬化和 HCC。导致 NAFLD 和 NASH 发生和进展的病理生理机制很复杂，因此针对不同病理生理机制的多种治疗方法正在研究中。基于肠促胰岛素的治疗方法，包括 GLP-1RAs 和 DPP-4 抑制剂以及 ASK1 通路的抑制，为该疾病的治疗提供了两种新的机制，这将是本综述的重点。
